ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

belumosudil

Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.

Drug pageBelumosudil: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 24, 202426 company-led studies, 6 open or runningNext primary completion: Jan 26, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only256 open or runningphase 4since Sep 24, 2024Apr 2, 2014Jan 26, 2027phase 1 · NCT07726914
BioNova Pharmaceuticals (Shanghai)10 open or runningphase 2since Jun 11, 2021Jun 11, 2021none ahead

Also a collaborator on its studies: Meiji Seika Pharma and Quotient Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioNova Pharmaceuticals (Shanghai) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2020Named belumosudilINNProposed as its International Nonproprietary Name in WHO's List 123 · before, KD025
  2. Jun 11, 2021First study: phase 2 study in Bronchiolitis Obliterans SyndromeFirst studyNCT04930562 · 30 enrolled · China

TargetBeta

ROCK1 →ROCK2 →read by rule
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
netarsudilruleAlconphase 420

Studies

The one study BioNova Pharmaceuticals (Shanghai) leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04930562Bronchiolitis Obliterans Syndrome · China2CompletedJun 10, 202230

How it is read

Names in the registry

  • “Belumosudil”, 15 entries
  • “Belumosudil (KD025)”, 3 entries
  • “Belumosudil mesylate”, 3 entries
  • “KD025”, 2 entries
  • “Belumosudil 200 mg QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.